Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
Kura Oncology (Nasdaq: KURA) has announced two upcoming virtual investor and analyst events focused on their farnesyl transferase inhibitor (FTI) program. The first event on September 16, 2025, will showcase preclinical data on combining FTI agents with targeted therapies including TKIs, RAS inhibitors, and PI3K alpha inhibitors.
The second event on October 18, 2025, will present clinical data from the ESMO Congress 2025, featuring the first clinical data from KO-2806, Kura's next-generation FTI. The company will present three posters at ESMO, including preliminary results from the FIT-001 phase 1 trial combining KO-2806 with cabozantinib in renal cell carcinoma, KO-2806 monotherapy data in advanced solid tumors, and Phase 1 results from the KURRENT-HN study.
Kura Oncology (Nasdaq: KURA) ha annunciato due prossimi eventi virtuali per investitori e analisti incentrati sul loro programma con inibitori della farnesil transferasi (FTI). Il primo evento, il 16 settembre 2025, presenterà dati preclinici sull’associazione degli FTI con terapie mirate, tra cui TKI, inibitori di RAS e inibitori di PI3K alfa.
Il secondo evento, il 18 ottobre 2025, esporrà i dati clinici dal Congresso ESMO 2025, mostrando i primi dati clinici su KO-2806, l’FTI di nuova generazione di Kura. L’azienda presenterà tre poster a ESMO, inclusi i risultati preliminari dello studio FIT-001 di fase 1 che combina KO-2806 con cabozantinib nel carcinoma renale, i dati in monoterapia di KO-2806 nei tumori solidi avanzati e i risultati di fase 1 dello studio KURRENT-HN.
Kura Oncology (Nasdaq: KURA) ha anunciado dos próximos eventos virtuales para inversores y analistas centrados en su programa de inhibidores de la farnesil transferasa (FTI). El primer evento, el 16 de septiembre de 2025, mostrará datos preclínicos sobre la combinación de agentes FTI con terapias dirigidas, incluidos TKI, inhibidores de RAS y inhibidores de PI3K alfa.
El segundo evento, el 18 de octubre de 2025, presentará datos clínicos del Congreso ESMO 2025, incluyendo los primeros datos clínicos de KO-2806, el FTI de próxima generación de Kura. La compañía presentará tres pósters en ESMO, que incluyen resultados preliminares del ensayo FIT-001 de fase 1 que combina KO-2806 con cabozantinib en carcinoma de células renales, datos de monoterapia de KO-2806 en tumores sólidos avanzados y los resultados de fase 1 del estudio KURRENT-HN.
Kura Oncology (Nasdaq: KURA)는 파르네실 전이효소 억제제(FTI) 프로그램을 중심으로 한 가상 투자자·애널리스트 행사를 두 차례 개최할 예정이라고 발표했습니다. 첫 번째 행사는 2025년 9월 16일에 열리며, FTI 제제와 TKI, RAS 억제제, PI3K 알파 억제제 등 표적 치료제의 병용에 대한 전임상 데이터를 공개합니다.
두 번째 행사는 2025년 10월 18일에 개최되며, ESMO 2025에서 발표된 임상 데이터를 발표합니다. 여기에는 Kura의 차세대 FTI인 KO-2806의 첫 임상 데이터가 포함됩니다. 회사는 ESMO에서 세 편의 포스터를 발표할 예정이며, 그 내용은 카보잔티닙과 KO-2806을 병용한 신장세포암에 대한 FIT-001 1상 시험의 예비 결과, 진행성 고형암에서의 KO-2806 단독요법 데이터, 그리고 KURRENT-HN 연구의 1상 결과입니다.
Kura Oncology (Nasdaq: KURA) a annoncé deux événements virtuels à venir destinés aux investisseurs et analystes, axés sur leur programme d’inhibiteurs de la farnésyltransférase (FTI). Le premier événement, le 16 septembre 2025, présentera des données précliniques sur la combinaison des agents FTI avec des thérapies ciblées, notamment des TKIs, des inhibiteurs de RAS et des inhibiteurs de PI3K alpha.
Le second événement, le 18 octobre 2025, dévoilera des données cliniques issues du Congrès ESMO 2025, incluant les premières données cliniques de KO-2806, le FTI de nouvelle génération de Kura. La société présentera trois posters à l’ESMO, dont les résultats préliminaires de l’essai de phase 1 FIT-001 combinant KO-2806 avec du cabozantinib dans le carcinome rénal, des données de monothérapie de KO-2806 dans des tumeurs solides avancées et les résultats de phase 1 de l’étude KURRENT-HN.
Kura Oncology (Nasdaq: KURA) hat zwei bevorstehende virtuelle Veranstaltungen für Investoren und Analysten angekündigt, die sich auf ihr Programm mit Farnesyltransferase-Inhibitoren (FTI) konzentrieren. Die erste Veranstaltung am 16. September 2025 wird präklinische Daten zur Kombination von FTI-Wirkstoffen mit zielgerichteten Therapien vorstellen, darunter TKIs, RAS-Inhibitoren und PI3K-alpha-Inhibitoren.
Die zweite Veranstaltung am 18. Oktober 2025 wird klinische Daten vom ESMO-Kongress 2025 präsentieren und die ersten klinischen Daten zu KO-2806, Kuras FTI der nächsten Generation, vorstellen. Das Unternehmen wird auf der ESMO drei Poster präsentieren, darunter vorläufige Ergebnisse der FIT-001 Phase-1-Studie, die KO-2806 mit Cabozantinib beim Nierenzellkarzinom kombiniert, Monotherapie-Daten zu KO-2806 bei fortgeschrittenen soliden Tumoren und Phase-1-Ergebnisse der KURRENT-HN-Studie.
- None.
- None.
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies
October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura’s leadership in targeting cancer signaling pathways to address unmet needs in solid tumors and hematologic malignancies.
Event Details:
- FTI Preclinical Program Review: Synergistic Combinations with Targeted Therapies
Tuesday, September 16, 2025
1:30 p.m. PT / 4:30 p.m. ET
This event will explore the scientific foundation, mechanisms of action and preclinical data supporting the combination of FTIs with tyrosine kinase inhibitors (TKIs), RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors. - Discussion of Clinical Data Presented at 2025 ESMO Congress, Including First Clinical Data from KO-2806, Kura’s Next-Generation FTI
Saturday, October 18, 2025
10:30 a.m. PT / 1:30 p.m. ET
This event will dive into clinical data presented at the 2025 European Society for Medical Oncology (ESMO) Congress, including the first clinical insights from KO-2806, Kura’s next-generation FTI, showcasing its potential to address resistance mechanisms in cancer.
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following both events.
Details of the presentations at ESMO Congress 2025 are as follows:
Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase 1 trial
Saturday, October 18, 2025; 12:00 PM CEST
Publication Number 2604P
A phase 1 study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors
Sunday, October 19, 2025; 12:00 PM CEST
Publication Number 981P
Tipifarnib (TIP) and alpelisib (ALP) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 1 results from KURRENT-HN
Monday, October 20, 2025; 12:00 PM CEST
Publication Number 1349P
The three posters presented at ESMO Congress 2025 will be available to view in the “Pipeline/Posters and Presentations” section on Kura’s website at approximately 12:05 a.m. PT / 3:05 a.m. ET on October 18, 2025.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of FTIs to transform treatment for solid tumors and to address resistance mechanisms in cancer. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
When will Kura Oncology (KURA) host its virtual investor events for its FTI program?
What clinical data will Kura Oncology present at ESMO Congress 2025?
Where can investors access Kura Oncology's virtual event presentations?
What is the focus of Kura Oncology's September 16 virtual event?
When will Kura Oncology's ESMO Congress 2025 posters be available to view?
